Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,624 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00725283 | Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 34 | GlaxoSmithKlineINDUSTRY | 2 | Aug 7, 2018 | clinicaltrials |
| NCT02317016 | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 4 | Jul 31, 2018 | clinicaltrials |
| NCT01971476 | Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known | completed | Phase 1 | 22 | Boehringer IngelheimINDUSTRY | 5 | Jul 30, 2018 | clinicaltrials |
| NCT01730612 | ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA(iTEPsein) | completed | Phase 1 / Phase 2 | 23 | Nantes University HospitalOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00398567 | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 45 | Puma Biotechnology, Inc.INDUSTRY | 4 | Jul 24, 2018 | clinicaltrials |
| NCT03235973 | Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes(CEREAL) | unknown | Phase 1 | 29 | Institut Paoli-CalmettesOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery | terminated | Phase 1 | 60 | GlaxoSmithKlineINDUSTRY | 6 | Jun 18, 2018 | clinicaltrials |
| NCT01532102 | Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts | completed | Phase 1 / Phase 2 | 24 | Anaconda PharmaINDUSTRY | 2 | May 30, 2018 | clinicaltrials |
| NCT02760797 | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 38 | Hoffmann-La RocheINDUSTRY | 3 | May 22, 2018 | clinicaltrials |
| NCT01636479 | Phase 1 Safety Testing of SAR405838 | completed | Phase 1 | 77 | SanofiINDUSTRY | 3 | May 17, 2018 | clinicaltrials |
| NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 170 | Eli Lilly and CompanyINDUSTRY | 6 | May 16, 2018 | clinicaltrials |
| NCT02077504 | Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) "CONDUCTOME"(CONDUCTOME) | terminated | Phase 1 | 28 | University Hospital, GrenobleOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02305056 | Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)(CARBONOMIC) | terminated | Phase 1 | 6 | University Hospital, GrenobleOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT03315091 | Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 3 | Apr 30, 2018 | clinicaltrials |
| NCT01875705 | A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 2 | Apr 6, 2018 | clinicaltrials |
| NCT02558140 | A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 120 | Hoffmann-La RocheINDUSTRY | 3 | Apr 4, 2018 | clinicaltrials |
| NCT01494688 | A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors | completed | Phase 1 | 217 | Hoffmann-La RocheINDUSTRY | 2 | Mar 16, 2018 | clinicaltrials |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | unknown | Phase 1 | 72 | Marjolein SpieringOTHER | 4 | Mar 13, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT01766583 | A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma(CLEAR) | completed | Phase 1 | 18 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02004106 | A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 110 | Hoffmann-La RocheINDUSTRY | 8 | Mar 6, 2018 | clinicaltrials |
| NCT02722551 | CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study(RELIEF) | withdrawn | Phase 1 / Phase 2 | 0 | Edwards LifesciencesINDUSTRY | 7 | Jan 9, 2018 | clinicaltrials |
| NCT00540943 | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Nov 29, 2017 | clinicaltrials |
| NCT02487823 | Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer(NCMPC-BKM) | terminated | Phase 1 | 6 | Institut Paoli-CalmettesOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT01192165 | Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | completed | Phase 1 | 169 | GlaxoSmithKlineINDUSTRY | 4 | Nov 13, 2017 | clinicaltrials |
| NCT00955773 | A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects(Cancer) | completed | Phase 1 | 64 | GlaxoSmithKlineINDUSTRY | 2 | Nov 9, 2017 | clinicaltrials |
| NCT02250118 | Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer(BEVAP) | terminated | Phase 1 | 1 | Institut CurieOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03294486 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients(ONCOVIRAC) | unknown | Phase 1 / Phase 2 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02216617 | Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy(TAPIS) | completed | Phase 1 | 8 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02906800 | Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients(DIGHANC) | unknown | Phase 1 / Phase 2 | 15 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01958996 | Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 27 | Poitiers University HospitalOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | completed | Phase 1 | 139 | Array BioPharmaINDUSTRY | 7 | Oct 2, 2017 | clinicaltrials |
| NCT01918254 | A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein | completed | Phase 1 | 66 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2017 | clinicaltrials |
| NCT01947322 | Haploidentical NK-cell Infusion in Acute Myeloid Leukemia(NK) | completed | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01569750 | A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | completed | Phase 1 | 33 | Janssen Research & Development, LLCINDUSTRY | 2 | Aug 22, 2017 | clinicaltrials |
| NCT02135159 | Patients With Brain Metastases From HER2-positive Breast Cancer(BIRTH) | completed | Phase 1 | 36 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT01677780 | An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies | completed | Phase 1 | 11 | Hoffmann-La RocheINDUSTRY | 3 | Jul 7, 2017 | clinicaltrials |
| NCT02020577 | Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours | completed | Phase 1 | 58 | Boehringer IngelheimINDUSTRY | 2 | Jun 22, 2017 | clinicaltrials |
| NCT02155582 | Copanlisib Pharmacodynamic Study | completed | Phase 1 | 63 | BayerINDUSTRY | 3 | Jun 16, 2017 | clinicaltrials |
| NCT00148928 | Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 2 | Jun 2, 2017 | clinicaltrials |
| NCT01469975 | First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10(SYNFRIZZ) | terminated | Phase 1 | 20 | Centre Leon BerardOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT00058526 | A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | completed | Phase 1 | 61 | GlaxoSmithKlineINDUSTRY | 5 | May 15, 2017 | clinicaltrials |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | terminated | Phase 1 | 71 | GlaxoSmithKlineINDUSTRY | 6 | May 15, 2017 | clinicaltrials |
| NCT01138033 | Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors | completed | Phase 1 | 74 | GlaxoSmithKlineINDUSTRY | 3 | May 11, 2017 | clinicaltrials |
| NCT01156870 | First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor | completed | Phase 1 | 114 | SanofiINDUSTRY | 3 | May 10, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials